EUVIMEDEUVIMED entdecken
Crossref

Enhanced Cytotoxic Activity of 6-Mercaptopurine–Loaded Solid Lipid Nanoparticles in Hepatic Cancer Treatment

Ahmet Doğan Ergin iD, Çağatay Oltulu, Büşra Koç

ASSAY and Drug Development Technologies · 2023

DOI: 10.1089/adt.2023.007 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ASSAY and Drug Development Technologies, 2023. Verfasst von Ahmet Doğan Ergin und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Nanotechnology, Institute of Health Sciences, Trakya University, Edirne, Turkey. Hauptthemen laut MEDLINE: Nanoparticles, Antineoplastic Agents, Liver Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 34 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

6-Mercaptopurine (6-MCP) is an antiproliferative purine analog used in acute lymphoblastic leukemia, non-Hodgkin lymphoma, and inflammatory bowel disease (Crohn's disease, ulcerative colitis). Although 6-MCP has the great therapeutic potential for cancer and immunosuppressant-related diseases, 6-MCP is not readily soluble in water, presents a high first-pass effect, short half-life (0.5-1.5 h), and implies a low bioavailability (16%). On the contrary, solid lipid nanoparticles (SLNs) are prepared from solid lipids at room temperature and body temperature. In this study, SLNs were prepared w/o/w double emulsion-solvent evaporation method using Precirol ATO5 as matrix lipid. In the emulsion stabilization, surfactant (Tween 80) and polymeric stabilizer (polyvinyl alcohol [PVA]) were used. Two group formulations using Tween 80 and PVA were compared in terms of particle size, polydispersity index, zeta potential encapsulation efficiency%, and process yield%. Differential calorimetric analysis and release properties were examined for optimum formulation, and release kinetics were calculated. According to studies, sustained release was obtained with SLNs by the Korsmayer-Peppas kinetic model. The in vitro cytotoxicity studies were performed on the hepatocarcinoma (HEP3G) cell line. According to the results, successful SLN formulations were produced, and PVA was found best stabilizer. Optimum formulation exhibited significantly higher cytotoxic effects on HEP3G than on pure 6-MCP. These results demonstrated that solid lipid nanodrug delivery systems have great potential for formulation of 6-MCP.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NanoparticlesAntineoplastic AgentsLiver NeoplasmsHumansMercaptopurinePolysorbatesEmulsionsLipidsLiposomes

Stichwörter der Autor:innen

6-mercaptopurinecell culturehepatic cancersolid lipid nanoparticletoxicity

Substanzen

MercaptopurinePolysorbatesEmulsionsAntineoplastic AgentsLipidsLipid NanoparticlesLiposomes

Autor:innen und Institutionen

  • Department of Pharmaceutical Nanotechnology, Institute of Health Sciences, Trakya University, Edirne, Turkey.
  • Department of Pharmaceutical Technology and Faculty of Pharmacy, Trakya University, Edirne, Turkey.
  • Department of Pharmaceutical Toxicology, Faculty of Pharmacy, Trakya University, Edirne, Turkey.

ORCID-Profile: Ahmet Doğan Ergin

Zitieren

APA

Ergin, A. D., Oltulu, Ç., & Koç, B. (2023). Enhanced Cytotoxic Activity of 6-Mercaptopurine–Loaded Solid Lipid Nanoparticles in Hepatic Cancer Treatment. ASSAY and Drug Development Technologies. https://doi.org/10.1089/adt.2023.007

Vancouver

Ergin AD, Oltulu Ç, Koç B. Enhanced Cytotoxic Activity of 6-Mercaptopurine–Loaded Solid Lipid Nanoparticles in Hepatic Cancer Treatment. ASSAY and Drug Development Technologies. 2023. doi:10.1089/adt.2023.007

BibTeX
@article{Ergin2023,
  author = {Ergin, Ahmet Doğan and Oltulu, Çağatay and Koç, Büşra},
  title = {Enhanced Cytotoxic Activity of 6-Mercaptopurine–Loaded Solid Lipid Nanoparticles in Hepatic Cancer Treatment},
  journal = {ASSAY and Drug Development Technologies},
  year = {2023},
  doi = {10.1089/adt.2023.007}
}
Kostenlos starten →